CAVA Group reported Q1 2026 results on May 19 and woke up Wednesday to a wall of raised price targets — yet the stock still fell 2.2% to $78.12, down 17.6% over the past month.
The analyst response to the print was almost uniformly constructive. At least eight firms raised their targets on Wednesday morning alone. Baird moved to $98 from $88. Stifel lifted to $105 from $90. RBC Capital nudged up to $105 from $100. Morgan Stanley edged its target to $86 from $85 while keeping its Equal-Weight rating — a signal that the sideline camp acknowledges the beat but still balks at the multiple. Barclays also raised its target, to $74 from $70, while holding Equal-Weight — the only firm with a target now sitting below the current price. The consensus mean has settled at $93.64, roughly 20% above Wednesday's close, but the split between the believers and the fence-sitters is real: most of the Street is Outperform or Buy, yet the two most prominent neutral voices, Morgan Stanley and Barclays, are pointing in opposite directions from the pack.
The bull case rests on CAVA's category leadership in Mediterranean fast-casual, operational improvements under recently installed COO leadership borrowed from Texas Roadhouse, and the durable tailwind of health-conscious consumer spending. Bears argue the valuation still demands perfection: even after the month's slide, the stock trades at roughly 129x trailing earnings and 44.5x EV/EBITDA. Both multiples have compressed over the past 30 days — PE down nearly 38 points, EV/EBITDA down about 2.4 turns — but compression from elevated to still-elevated is not the same as becoming cheap. The path to 1,200 U.S. stores by 2033 is the growth engine; whether the current multiple prices that in fully is exactly what bulls and bears are debating.
Short positioning tells a quieter story than the price action suggests. SI has stayed essentially flat on the week — up less than 0.1% — at 10.8% of free float, and remains well below the peak of roughly 15.6% hit in early April. That six-week unwind, documented in prior notes, has stalled rather than reversed. Cost to borrow is negligible at 0.43%, and availability in the lending pool has actually loosened, running at 359% of short interest versus around 111% at the April tights. There is no borrow squeeze pressure here. The short score has also eased, drifting from near 60 a week ago to 58 today, reflecting the more moderate positioning environment.
Options sentiment has nudged slightly more defensive after the print. The put/call ratio is 0.64, about one standard deviation above its 20-day average of 0.60 — elevated but not alarming, and well short of the 0.91 peak seen earlier in the year. That's a meaningful step down from the 2.4 standard-deviation reading cited in the pre-earnings note published Monday. The defensive hedging that built ahead of May 19 appears to have partially unwound.
The earnings history adds useful context. The last confirmed print with price data — Q4 2025, reported May 12 — produced a 9.6% single-day drop and a 2.3% five-day decline. The Q1 2026 day-one reaction of -2.2% is comparatively mild. What to watch next is whether the analyst upgrade cycle translates into institutional buying that narrows the gap to the $93.64 consensus target, or whether the stock continues to trade below the Street's collective conviction ahead of the next earnings event, currently scheduled for June 22.
See the live data behind this article on ORTEX.
Open CAVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
